Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis

Julien Rossignol¹, Sophie Georgin-Lavialle², Danielle Canioni³, Omer Beganovic⁴, Chantal Brouzes⁴, Olivier Fain⁵, Maël Heiblig⁶, Clément Gourguechon⁷, Philippe Guilpain⁸, Cristina Bulai-Livideanu⁹, Stéphane Barete¹⁰, Julie Agopian¹¹, Fabienne Brenet¹¹, Patrice Dubreuil¹¹, Richard Lemal¹², Olivier Tournilhac¹², Louis Terriou¹³, David Launay¹⁴, Laurence Bouillet¹⁵, Catharina Chatain¹⁵, Ghandi Damaj¹⁶, Thomas Ballul¹, Celine Greco¹⁷, Laura Polivka¹⁸, Laurent Frenzel¹, Cécile Meni¹, Hassiba Bouktit¹, Dina Benabou¹, Clotilde Devin¹, Caroline Gaudy-Marqueste¹⁹, Marie Gousseff²⁰, Edwige Le Mouel²¹, Antoine Neel²², Dana Ranta²³, Roland Jaussaud²⁴, Thierry Jo Molina³, Julie Bruneau³, Rose-Marie Javier²⁵, Fabien Pelletier²⁶, Florence Castelain²⁶, Frederique Retornaz²⁷, Quentin Cabrera²⁸, Patricia Zunic²⁸, Marie Pierre Gourin²⁹, Ewa Wierzbicka-Hainaut³⁰, Jean François Viallard³¹, Christian Lavigne³², Cyrille Hoarau³³, Isabelle Durieu³⁴, Sophie Dimicoli-Salazar³⁵, Jose Miguel Torregrosa-Diaz³⁶, Audrey Duval³⁷, Nicolas Garcelon³⁷, Jeremie Lespinasse³⁸, Angèle Soria³⁹, Yannick Chantran⁴⁰, Michel Arock⁴¹, Christine Bodemer¹⁸, Olivier Lortholary¹, Vahid Asnafi⁴, Olivier Hermine¹, Ludovic Lhermitte⁴²

Affiliations

¹ CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children's Hospital, Paris Centre University, Paris.
² Department of Internal Medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris.
³ CEREMAST, Department of Pathology, Necker-Children's Hospital, AP-HP, Paris Centre University, Paris.
⁴ Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France; Hôpital Necker Enfants-Malades, Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris.
⁵ Department of Internal Medicine, Sorbonne University, Saint-Antoine Hospital, AP-HP, Paris.
⁶ CEREMAST, Department of Hematology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite.
⁷ Department of Hematology, Amiens University Hospital, Amiens.
⁸ CEREMAST, Department of Internal Medicine-Multi-organ Diseases, Saint-Eloi University Hospital, Montpellier University, Montpellier.
⁹ CEREMAST, Department of Dermatology, Hôpital Larrey, CHU Toulouse, Toulouse.
¹⁰ CEREMAST, Dermatology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris.
¹¹ Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille.
¹² CEREMAST, Adult Clinical Hematology, CHU Clermont-Ferrand, INSERM CIC501, EA 7453 - Clermont Auvergne University, Clermont-Ferrand.
¹³ CEREMAST, Department of Internal Medicine and Clinical Immunology, Claude Huriez hospital, CHRU Lille, Lille.
¹⁴ CEREMAST, Department of Internal Medicine and Clinical Immunology, Claude Huriez hospital, CHRU Lille, Lille, France; Lille University, INSERM U995 LIRIC, CHU Lille, and Referral Center for Rare Systemic Autoimmune Diseases North and North-West of France, Lille.
¹⁵ CEREMAST, Clinical Immunology/Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble.
¹⁶ CEREMAST, Hematology Institute, Normandy University School of Medicine, Caen.
¹⁷ CEREMAST, Department of Pain and Palliative Care Unit, Necker-Children's Hospital, AP-HP, Paris Centre University, Paris.
¹⁸ CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children's Hospital, Paris Centre University, Paris, France; Department of Dermatology, Reference Center for Genodermatoses (MAGEC), AP-HP, Necker-Children's Hospital, Paris Centre University, Paris.
¹⁹ CEREMAST, Department of Dermatology, Aix-Marseille University, CHU Timone, Marseille.
²⁰ Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique, Vannes.
²¹ CEREMAST, Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes.
²² CEREMAST, Department of Internal Medicine, Hôtel-Dieu University Hospital, Nantes.
²³ Department of Hematology, Nancy University Hospital, Nancy.
²⁴ Department of Internal Medicine and Clinical Immunology, Vandoeuvre-lès-Nancy.
²⁵ CEREMAST, Department of Rheumatology, Strasbourg University Hospital, Strasbourg.
²⁶ CEREMAST, Department of Dermatology, Allergology Unit, University Hospital of Besançon, Besançon.
²⁷ Unité de soins et de recherche en médecine interne et maladies infectieuses, European hospital, Marseille.
²⁸ Department of Hematology, Sud Reunion University Hospital, Saint Pierre, La Réunion.
²⁹ CEREMAST, Department of Hematology, CHU Dupuytren, Limoges.
³⁰ CEREMAST, Department of Dermatology, CHU de Poitiers, Poitiers.
³¹ Department of Internal Medicine and Infectious Diseases, Haut-Lévêque Hospital, CHRU Bordeaux; Bordeaux University, Bordeaux.
³² CEREMAST, Department of Internal Medicine and Clinical Immunology, University Hospital, Angers.
³³ CEREMAST, Department of Clinical Immunology and Allergology, CHRU Tours, Tours.
³⁴ CEREMAST, Department of Internal Medicine, Adult Cystic Fibrosis Care Center, Hospices Civils de Lyon, Lyon.
³⁵ Department of Hematology, CHU Bordeaux, Bordeaux.
³⁶ Department of Hematology, CHU Poitiers, Poitiers.
³⁷ Paris Centre University, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris.
³⁸ eXYSTAT, Malakoff.
³⁹ CEREMAST, Department of Dermatology and Allergy, Tenon Hospital, Sorbonne University, Paris.
⁴⁰ CEREMAST, Department of Biological Immunology, Saint-Antoine Hospital, Sorbonne University, Paris.
⁴¹ CEREMAST, Laboratory of Hematology, Pitié-Salpêtrière Hospital, AP-HP, Paris Sorbonne University.
⁴² Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France; Hôpital Necker Enfants-Malades, Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris. ludovic.lhermitte@aphp.fr.

PMID: 39219498
PMCID: PMC11694130
DOI: 10.3324/haematol.2024.285740

Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis

Julien Rossignol et al. Haematologica. 2025.

. 2025 Jan 1;110(1):222-227.

doi: 10.3324/haematol.2024.285740.

Authors

Affiliations

¹ CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children's Hospital, Paris Centre University, Paris.
² Department of Internal Medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris.
³ CEREMAST, Department of Pathology, Necker-Children's Hospital, AP-HP, Paris Centre University, Paris.
⁴ Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France; Hôpital Necker Enfants-Malades, Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris.
⁵ Department of Internal Medicine, Sorbonne University, Saint-Antoine Hospital, AP-HP, Paris.
⁶ CEREMAST, Department of Hematology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite.
⁷ Department of Hematology, Amiens University Hospital, Amiens.
⁸ CEREMAST, Department of Internal Medicine-Multi-organ Diseases, Saint-Eloi University Hospital, Montpellier University, Montpellier.
⁹ CEREMAST, Department of Dermatology, Hôpital Larrey, CHU Toulouse, Toulouse.
¹⁰ CEREMAST, Dermatology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris.
¹¹ Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille.
¹² CEREMAST, Adult Clinical Hematology, CHU Clermont-Ferrand, INSERM CIC501, EA 7453 - Clermont Auvergne University, Clermont-Ferrand.
¹³ CEREMAST, Department of Internal Medicine and Clinical Immunology, Claude Huriez hospital, CHRU Lille, Lille.
¹⁴ CEREMAST, Department of Internal Medicine and Clinical Immunology, Claude Huriez hospital, CHRU Lille, Lille, France; Lille University, INSERM U995 LIRIC, CHU Lille, and Referral Center for Rare Systemic Autoimmune Diseases North and North-West of France, Lille.
¹⁵ CEREMAST, Clinical Immunology/Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble.
¹⁶ CEREMAST, Hematology Institute, Normandy University School of Medicine, Caen.
¹⁷ CEREMAST, Department of Pain and Palliative Care Unit, Necker-Children's Hospital, AP-HP, Paris Centre University, Paris.
¹⁸ CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children's Hospital, Paris Centre University, Paris, France; Department of Dermatology, Reference Center for Genodermatoses (MAGEC), AP-HP, Necker-Children's Hospital, Paris Centre University, Paris.
¹⁹ CEREMAST, Department of Dermatology, Aix-Marseille University, CHU Timone, Marseille.
²⁰ Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique, Vannes.
²¹ CEREMAST, Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes.
²² CEREMAST, Department of Internal Medicine, Hôtel-Dieu University Hospital, Nantes.
²³ Department of Hematology, Nancy University Hospital, Nancy.
²⁴ Department of Internal Medicine and Clinical Immunology, Vandoeuvre-lès-Nancy.
²⁵ CEREMAST, Department of Rheumatology, Strasbourg University Hospital, Strasbourg.
²⁶ CEREMAST, Department of Dermatology, Allergology Unit, University Hospital of Besançon, Besançon.
²⁷ Unité de soins et de recherche en médecine interne et maladies infectieuses, European hospital, Marseille.
²⁸ Department of Hematology, Sud Reunion University Hospital, Saint Pierre, La Réunion.
²⁹ CEREMAST, Department of Hematology, CHU Dupuytren, Limoges.
³⁰ CEREMAST, Department of Dermatology, CHU de Poitiers, Poitiers.
³¹ Department of Internal Medicine and Infectious Diseases, Haut-Lévêque Hospital, CHRU Bordeaux; Bordeaux University, Bordeaux.
³² CEREMAST, Department of Internal Medicine and Clinical Immunology, University Hospital, Angers.
³³ CEREMAST, Department of Clinical Immunology and Allergology, CHRU Tours, Tours.
³⁴ CEREMAST, Department of Internal Medicine, Adult Cystic Fibrosis Care Center, Hospices Civils de Lyon, Lyon.
³⁵ Department of Hematology, CHU Bordeaux, Bordeaux.
³⁶ Department of Hematology, CHU Poitiers, Poitiers.
³⁷ Paris Centre University, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris.
³⁸ eXYSTAT, Malakoff.
³⁹ CEREMAST, Department of Dermatology and Allergy, Tenon Hospital, Sorbonne University, Paris.
⁴⁰ CEREMAST, Department of Biological Immunology, Saint-Antoine Hospital, Sorbonne University, Paris.
⁴¹ CEREMAST, Laboratory of Hematology, Pitié-Salpêtrière Hospital, AP-HP, Paris Sorbonne University.
⁴² Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France; Hôpital Necker Enfants-Malades, Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris. ludovic.lhermitte@aphp.fr.

PMID: 39219498
PMCID: PMC11694130
DOI: 10.3324/haematol.2024.285740

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
**Outcomes of advanced systemic mastocytosis patients treated with midostaurin or cladribine according to CD2 expression on mast cells.** (A) Kaplan-Meier estimates of overall survival (OS) according to CD2 expression on bone marrow (BM) mast cells in midostaurin-treated patients with advanced systemic mastocytosis (Adv-SM). (B) Kaplan-Meier estimates of time to treatment failure (TTF) according to CD2 expression on BM mast cells in cladribine-treated patients with Adv-SM. OS and TTF since the start of treatment for each group were analyzed using the Kaplan-Meier estimator. Estimates of hazard functions were compared using the log rank test. CI: Confidence Interval; NA: not achieved.

See this image and copyright information in PMC

References

1. Valent P, Akin C, Hartmann K, et al. . Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646. - PMC - PubMed
1. Wang SA, Orazi A, Gotlib J, et al. . The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286-1306. - PubMed
1. Arock M, Hoermann G, Sotlar K, et al. . Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J Allergy Clin Immunol. 2022;149(6):1855-1865. - PubMed
1. Yang Y, Létard S, Borge L, et al. . Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood. 2010;116(7):1114-1123. - PubMed
1. Sánchez-Muñoz L, Morgado JM, Álvarez-Twose I, et al. . Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol. 2016;172(1):56-63. - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis

Affiliations

Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis

Authors

Affiliations

Figures

References

LinkOut - more resources

Full Text Sources